ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Acadia Pharmaceuticals Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.919 as well so absolutely I think you should be thinking about two main factors you know 00:00:04.919 -- 00:00:09.806 new patient starts and active patients because it's going to be the active patients that 00:00:09.806 -- 00:00:13.452 we believe that we can continue to grow over time that are really going to be meaningful 00:00:13.452 -- 00:00:15.595 for the ongoing revenue 00:00:15.595 -- 00:00:19.015 uptick for this brand into the long term 00:00:19.015 -- 00:00:22.360 Liz, do you want to touch on our positioning versus the new Celina product? 00:00:22.360 -- 00:00:22.760 Sure. 00:00:22.740 -- 00:00:27.747 I'll start out with the fact that, I mean, we're delighted for the PWS community 00:00:27.747 -- 00:00:31.852 that there is now a first therapy available for them. 00:00:31.852 -- 00:00:37.260 That said, I think we see this as an area of significant high unmet need and complex 00:00:37.260 -- 00:00:40.584 patients who are dealing with a number of different challenges. 00:00:40.584 -- 00:00:45.912 It's the kind of space where we think that it's likely that there is going to be absolutely 00:00:45.912 -- 00:00:51.656 room for multiple agents that are used with different MOAs, with different 00:00:51.656 -- 00:00:55.862 benefit-risk profiles that physicians can use according to the patient that's in front 00:00:55.862 -- 00:01:00.147 of them. I don't know if there's anything you want to add here, Tom? 00:01:00.147 -- 00:01:04.672 Well, the only thing I would add is we know that the Prada Willy population, you know, 00:01:04.672 -- 00:01:08.297 they have very complex and distinct needs, and we actually believe that there's going 00:01:08.297 -- 00:01:13.304 to be an opportunity for more than one product to play here, and I think with ...